Novartis gets anti-TGFb antibody from Xoma
Executive Summary
Novartis AG received exclusive worldwide rights to develop and commercialize Xoma Corp.'s anti-transforming growth factor-beta (TGFb) antibody XOMA089, in late preclinical testing for cancer. Xoma transferred related know-how, materials, and inventory to Novartis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice